| CAS ID: | 211448-85-0 |
| Molecular Formula: | C18H27N5O21P4 |
| Molecular Weight: | 773.3 g/mol |
| Monoisotopic Mass: | 773.0149 g/mol |
| Class: | Small Molecule |
| Natural Product: | No |
| Other Names: | DENUFOSOL TETRASODIUM | DENUFOSOL | INS37217 |
| Analysis: | Drug repositioning mechanism analysis |
| InChI: | InChI=1S/C18H27N5O21P4/c19-11-1-3-22(17(28)20-11)13-5-8(24)9(40-13)6-38-45(30,31)42-47(34,35)44-48(36,37)43-46(32,33)39-7-10-14(26)15(27)16(41-10)23-4-2-12(25)21-18(23)29/h1-4,8-10,13-16,24,26-27H,5-7H2,(H,30,31)(H,32,33)(H,34,35)(H,36,37)(H2,19,20,28)(H,21,25,29)/t8-,9+,10+,13+,14+,15+,16+/m0/s1 | See All |
| InChI Key: | FPNPSEMJLALQSA-MIYUEGBISA-N | |
| Smiles: | NC1=NC(=O)N(C=C1)[C@H]2C[C@H](O)[C@@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]3O[C@H]([C@H](O)[C@@H]3O)N4C=CC(=O)NC4=O)O2 | See All |
| Molfile: | Download |
Trial Record 1
| ClinicalTrial ID | NCT00056147 | Disease | Cystic fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | March 7, 2003 | Last Verified | January 29, 2015 |
| Sponsor | Merck Sharp & Dohme Corp. | ||
Trial Record 2
| ClinicalTrial ID | NCT00625612 | Disease | Cystic fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | February 28, 2008 | Last Verified | November 2, 2015 |
| Sponsor | Merck Sharp & Dohme Corp. | ||
Trial Record 3
| ClinicalTrial ID | NCT00130182 | Disease | Cystic fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | August 15, 2005 | Last Verified | May 22, 2013 |
| Sponsor | Merck Sharp & Dohme Corp. | ||
Trial Record 4
| ClinicalTrial ID | NCT00103714 | Disease | Cystic fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | February 15, 2005 | Last Verified | October 20, 2015 |
| Sponsor | Merck Sharp & Dohme Corp. | ||
Trial Record 5
| ClinicalTrial ID | NCT00357279 | Disease | Cystic fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | July 27, 2006 | Last Verified | November 4, 2015 |
| Sponsor | Merck Sharp & Dohme Corp. | ||
Trial Record 6
| ClinicalTrial ID | NCT00425165 | Disease | Cystic fibrosis |
| Phase | Phase 2 | Status | Terminated |
| First Received | January 22, 2007 | Last Verified | April 3, 2015 |
| Sponsor | Merck Sharp & Dohme Corp. | ||
Trial Record 7
| ClinicalTrial ID | NCT00034515 | Disease | Cystic fibrosis |
| Phase | Phase 1,Phase 2 | Status | Completed |
| First Received | April 30, 2002 | Last Verified | February 16, 2015 |
| Sponsor | Merck Sharp & Dohme Corp. | ||
Trial Record 8
| ClinicalTrial ID | NCT00846781 | Disease | Cystic fibrosis |
| Phase | Phase 3 | Status | Terminated |
| First Received | February 19, 2009 | Last Verified | November 6, 2015 |
| Sponsor | Merck Sharp & Dohme Corp. | ||
Trial Record 9
| ClinicalTrial ID | NCT01181622 | Disease | Cystic fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | August 13, 2010 | Last Verified | January 13, 2015 |
| Sponsor | Merck Sharp & Dohme Corp. | ||
| PubChem: | 9875516 |
| ChEMBL: | CHEMBL507282 |